Evotec

Evotec has started a research collaboration with Plectonic Biotech to investigate a new immunotherapy approach and the combination of the BiTco platform with LOGIBODY technology for the treatment of solid tumors. Financial details of the collaboration were not disclosed. Despite the news, Evotec's share briefly fell to a multi-year low of €3.13; there remains a lack of news to support a sustained trend reversal and confidence in the capital markets. » Más en deraktionaer.de

Evotec reports a 19.2% decline in revenue for H1/2026 to just over €300 million and an adjusted negative EBITDA of €42.7 million. Management attributes the weakness to delayed revenue recognition and lowers the full-year forecast, but expects a pickup in the fourth quarter from increased activity in discovery and preclinical development. To finance » Más en finanzen.net

Evotec published final H1 figures that match the preliminary July numbers: half-year revenue €300.1m, adjusted group EBITDA -€42.7m. The full-year outlook remains €570–610m in revenue and an EBITDA of -€70m to -€105m. Half-year revenue is 19.2% below the prior year, and the biologics business contracted 29.3% due to Sandoz effects. Two downward revisions to guidance have caused the share price to fall by more than one-third year-to-date, although the core business could be evaluated in a more differentiated way. » Más en finanzen.net